SARS-CoV-2 Antibodies in Human Milk After mRNA and Adenovector-Based Vaccination: A Systematic Review and Meta-Analysis.

IF 2.1 4区医学 Q2 NURSING

Journal of Human Lactation Pub Date : 2024-08-01 Epub Date: 2024-05-26 DOI:10.1177/08903344241252645

Xuan Li, Yan Hu, You Lv, Nathan Obore, YiXiao Wang, Hong Yu

{"title":"SARS-CoV-2 Antibodies in Human Milk After mRNA and Adenovector-Based Vaccination: A Systematic Review and Meta-Analysis.","authors":"Xuan Li, Yan Hu, You Lv, Nathan Obore, YiXiao Wang, Hong Yu","doi":"10.1177/08903344241252645","DOIUrl":null,"url":null,"abstract":"Background: SARS-CoV-2 specific antibodies exist in human milk expressed by lactating parents after vaccination. In the existing research, the effects of vaccine types on human milk are inconsistent.Research aim: This study aims to perform a systematic review and meta-analysis of the existing observational studies to compare the positive rates of SARS-CoV-2 specific antibodies in human milk according to mRNA and adenovector-based vaccination.Methods: PubMed, Web of Science, Elsevier Science Direct and Cochrane Library databases were systematically searched for relevant articles published from December 30, 2019 to February 15, 2023. Observational studies were considered eligible provided they reported data on SARS-CoV-2 specific antibodies in human milk. The risk of bias in non-randomized studies of interventions (ROBINS-I) tool, the Newcastle-Ottawa Scale (NOS), and the Agency for Healthcare Research and Quality (AHRQ) were used to assess risk of bias. Seven studies, including 511 lactating participants, were included in this review and meta-analysis.Results: The positive rate of SARS-CoV-2 IgA is higher in mRNA vaccine groups than in adenovector-based vaccine groups (OR = 4.80, 95% CI [3.04, 7.58], p < 0.001). The positive rate of SARS-CoV-2 IgG was higher in mRNA vaccines than in adenovector-based vaccines.Conclusions: Compared to adenovector-based vaccines, mRNA vaccines present a higher positivity rate of IgA and IgG in human milk after vaccination. In other words, mRNA vaccinations may offer breastfed children a higher level of protection than adenovector-based vaccinations. Further high-quality data is still required to substantiate these findings.","PeriodicalId":15948,"journal":{"name":"Journal of Human Lactation","volume":" ","pages":"425-433"},"PeriodicalIF":2.1000,"publicationDate":"2024-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Human Lactation","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/08903344241252645","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/5/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"NURSING","Score":null,"Total":0}

引用次数: 0

Abstract

Background: SARS-CoV-2 specific antibodies exist in human milk expressed by lactating parents after vaccination. In the existing research, the effects of vaccine types on human milk are inconsistent.

Research aim: This study aims to perform a systematic review and meta-analysis of the existing observational studies to compare the positive rates of SARS-CoV-2 specific antibodies in human milk according to mRNA and adenovector-based vaccination.

Methods: PubMed, Web of Science, Elsevier Science Direct and Cochrane Library databases were systematically searched for relevant articles published from December 30, 2019 to February 15, 2023. Observational studies were considered eligible provided they reported data on SARS-CoV-2 specific antibodies in human milk. The risk of bias in non-randomized studies of interventions (ROBINS-I) tool, the Newcastle-Ottawa Scale (NOS), and the Agency for Healthcare Research and Quality (AHRQ) were used to assess risk of bias. Seven studies, including 511 lactating participants, were included in this review and meta-analysis.

Results: The positive rate of SARS-CoV-2 IgA is higher in mRNA vaccine groups than in adenovector-based vaccine groups (OR = 4.80, 95% CI [3.04, 7.58], p < 0.001). The positive rate of SARS-CoV-2 IgG was higher in mRNA vaccines than in adenovector-based vaccines.

Conclusions: Compared to adenovector-based vaccines, mRNA vaccines present a higher positivity rate of IgA and IgG in human milk after vaccination. In other words, mRNA vaccinations may offer breastfed children a higher level of protection than adenovector-based vaccinations. Further high-quality data is still required to substantiate these findings.

查看原文本刊更多论文

接种 mRNA 和腺病毒载体疫苗后人乳中的 SARS-CoV-2 抗体：系统回顾与元分析》。

背景：接种SARS-CoV-2疫苗后，哺乳父母分泌的母乳中存在SARS-CoV-2特异性抗体。研究目的：本研究旨在对现有的观察性研究进行系统回顾和荟萃分析，比较基于 mRNA 和腺病毒的疫苗接种后母乳中 SARS-CoV-2 特异性抗体的阳性率：系统检索了 PubMed、Web of Science、Elsevier Science Direct 和 Cochrane Library 数据库中 2019 年 12 月 30 日至 2023 年 2 月 15 日期间发表的相关文章。只要观察性研究报告了母乳中 SARS-CoV-2 特异性抗体的数据，就符合条件。非随机干预研究中的偏倚风险（ROBINS-I）工具、纽卡斯尔-渥太华量表（NOS）和美国医疗保健研究与质量机构（AHRQ）被用于评估偏倚风险。本综述和荟萃分析纳入了七项研究，其中包括 511 名哺乳期参与者：mRNA疫苗组的SARS-CoV-2 IgA阳性率高于腺病毒疫苗组（OR = 4.80，95% CI [3.04，7.58]，P 结论：与腺病毒疫苗相比，mRNA疫苗组的SARS-CoV-2 IgA阳性率更高：与腺病毒疫苗相比，mRNA 疫苗接种后人乳中的 IgA 和 IgG 阳性率更高。换句话说，与腺病毒疫苗相比，mRNA 疫苗可为母乳喂养的儿童提供更高水平的保护。要证实这些发现，还需要更多高质量的数据。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Human Lactation 医学-妇产科学

CiteScore

5.00

自引率

11.50%

发文量

100

审稿时长

6-12 weeks

期刊介绍： Committed to the promotion of diversity and equity in all our policies and practices, our aims are: To provide our readers and the international communities of clinicians, educators and scholars working in the field of lactation with current and quality-based evidence, from a broad array of disciplines, including the medical sciences, basic sciences, social sciences and the humanities. To provide student and novice researchers, as well as, researchers whose native language is not English, with expert editorial guidance while preparing their work for publication in JHL. In each issue, the Journal of Human Lactation publishes original research, original theoretical and conceptual articles, discussions of policy and practice issues, and the following special features: Advocacy: A column that discusses a ‘hot’ topic in lactation advocacy About Research: A column focused on an in-depth discussion of a different research topic each issue Lactation Newsmakers: An interview with a widely-recognized outstanding expert in the field from around the globe Research Commentary: A brief discussion of the issues raised in a specific research article published in the current issue Book review(s): Reviews written by content experts about relevant new publications International News Briefs: From major international lactation organizations.